Trends and Outcomes of Patent Ductus Arteriosus Treatment in Very Preterm Infants in Canada

Abstract

Objective To assess trends in patent ductus arteriosus (PDA) management and examine concurrent changes in neonatal mortality and morbidities.

Methods This retrospective observational study examined infants born at 23 to 32 weeks' gestational age with PDA and admitted to a neonatal unit during 2006 to 2012. Multivariable logistic regression assessed trends in yearly PDA treatment rates and compared a composite outcome of mortality or any severe morbidity (bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, or necrotizing enterocolitis) between and within time periods and PDA treatments.

Results Study subjects included 5,824 preterm neonates with clinical/echocardiographic PDA diagnosis. During 2006 to 2012, conservative management increased (14–38%), whereas pharmacotherapy-only (58–49%), surgical ligation-only (7.1–2.5%), and both pharmacotherapy and surgical ligation (21–10%) decreased (p-values <0.01). From 2006 to 2008 and 2009 to 2012, the composite outcome decreased for infants managed conservatively (AOR = 0.70, 95% CI 0.52–0.92), with no changes detected for pharmacotherapy and/or ligation. Lower composite outcome after conservative management versus pharmacotherapy-only during 2009 to 2012 (AOR = 0.61, 95% CI 0.51–0.74), but not during 2006 to 2008 reflect significant effect modification by time period.

Conclusion In Canada, during 2006 to 2012, conservative PDA management increased while pharmacotherapy and/or surgical ligation decreased. Lower composite outcome was detected during later years after increases in conservative management; however, bias due to unmeasured confounders remains possible.

Keywords

infant - neonatal morbidities - neonatal mortality - patent ductus arteriosus - premature

• References

• 1 Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 2005; 40 (2) 184-188
• 2 Noori S, McCoy M, Friedlich P , et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009; 123 (1) e138-e144
• 3 Schena F, Francescato G, Cappelleri A , et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr 2015; 166 (6) 1488-1492
• 4 Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?. J Perinatol 2010; 30 (4) 241-252
• 5 Jain A, Shah PS. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates. JAMA Pediatr 2015; 169 (9) 863-872
• 6 Hoellering AB, Cooke L. The management of patent ductus arteriosus in Australia and New Zealand. J Paediatr Child Health 2009; 45 (4) 204-209
• 7 Isayama T, Lee SK, Mori R , et al; Canadian Neonatal Network; Neonatal Research Network of Japan. Comparison of mortality and morbidity of very low birth weight infants between Canada and Japan. Pediatrics 2012; 130 (4) e957-e965
• 8 Isayama T, Mirea L, Mori R , et al; Neonatal Research Network of Japan and the Canadian Neonatal Network. Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches. Am J Perinatol 2015; 32 (11) 1087-1094
• 9 Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007; 119 (6) 1165-1174
• 10 Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A ; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150 (3) 229-234 , 234.e1
• 11 Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat?. J Perinatol 2010; 30 (Suppl): S31-S37
• 12 O'Donovan DJ, Baetiong A, Adams K , et al. Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. J Perinatol 2003; 23 (4) 286-290
• 13 Kaempf JW, Wu YX, Kaempf AJ, Kaempf AM, Wang L, Grunkemeier G. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants?. J Perinatol 2012; 32 (5) 344-348
• 14 Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes. J Perinatol 2007; 27 (3) 164-170
• 15 Madan JC, Kendrick D, Hagadorn JI, Frantz III ID ; National Institute of Child Health and Human Development Neonatal Research Network. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009; 123 (2) 674-681
• 16 Mirea L, Sankaran K, Seshia M , et al; Canadian Neonatal Network. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012; 161 (4) 689-694.e1
• 17 Weisz DE, More K, McNamara PJ, Shah PS. PDA ligation and health outcomes: a meta-analysis. Pediatrics 2014; 133 (4) e1024-e1046
• 18 Chock VY, Punn R, Oza A , et al. Predictors of bronchopulmonary dysplasia or death in premature infants with a patent ductus arteriosus. Pediatr Res 2014; 75 (4) 570-575
• 19 Brooks JM, Travadi JN, Patole SK, Doherty DA, Simmer K. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 2005; 90 (3) F235-F239
• 20 Canadian Neonatal Network. Canadian Neonatal Network Abstractor's Manual. v 2.1.2, 1–94. 2014. Canadian Neonatal Network. Available at: http://www.canadianneonatalnetwork.org/Portal/LinkClick.aspx?fileticket=krvGeUTtLck%3d&tabid=69 . Accessed August 20, 2015
• 21 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92 (4) 529-534
• 22 International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123 (7) 991-999
• 23 Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82 (4) 527-532
• 24 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33 (1) 179-201
• 25 Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risk scores. J Pediatr 2001; 138 (1) 92-100
• 26 Kramer MS, Platt RW, Wen SW , et al; Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001; 108 (2) E35
• 27 Godambe S, Newby B, Shah V, Shah PS. Effect of indomethacin on closure of ductus arteriosus in very-low-birthweight neonates. Acta Paediatr 2006; 95 (11) 1389-1393
• 28 Toyoshima K, Momma K, Nakanishi T. In vivo dilatation of the ductus arteriosus induced by furosemide in the rat. Pediatr Res 2010; 67 (2) 173-176
• 29 De Buyst J, Rakza T, Pennaforte T, Johansson AB, Storme L. Hemodynamic effects of fluid restriction in preterm infants with significant patent ductus arteriosus. J Pediatr 2012; 161 (3) 404-408
• 30 Fajardo MF, Claure N, Swaminathan S , et al. Effect of positive end-expiratory pressure on ductal shunting and systemic blood flow in preterm infants with patent ductus arteriosus. Neonatology 2014; 105 (1) 9-13
• 31 McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92 (6) F424-F427